According to a recent LinkedIn post from Forge Biologics, the company is involved in a new manufacturing partnership with The Progeria Research Foundation focused on gene therapy for Progeria, a rare and fatal genetic disease. The post indicates that Forge will contribute process development and manufacturing expertise in collaboration with prominent researchers including Drs. Leslie Gordon, David R. Liu, and Francis Collins.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that this collaboration may reinforce Forge Biologics’ positioning as a specialist contract development and manufacturing organization in advanced genetic medicines. For investors, increased visibility in high-profile, mission-driven rare disease programs could support future business development opportunities and validate the company’s capabilities in complex gene therapy manufacturing.
While the post does not provide financial terms, such partnerships could translate into recurring revenue streams if programs advance successfully through clinical stages. Engagement with globally recognized scientific leaders and patient foundations may also enhance Forge’s reputation in the gene therapy ecosystem, potentially improving its competitiveness for additional outsourcing and co-development projects.